Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12624001183572p
Ethics application status
Not yet submitted
Date submitted
2/09/2024
Date registered
27/09/2024
Date last updated
27/09/2024
Date data sharing statement initially provided
27/09/2024
Type of registration
Prospectively registered
Titles & IDs
Public title
Safety and efficacy of sodium glucose cotransporter 2 inhibitors following cardiac arrest for hypoxic brain injury
Query!
Scientific title
Effect of SGLT2 inhibitors on cerebral injury and outcomes in comatose Out-Of-Hospital Cardiac Arrest survivors - a pilot study
Query!
Secondary ID [1]
312872
0
Nil known
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
PRIME-OOHCA
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
cardiac arrest
335021
0
Query!
hypoxic brain injury
335022
0
Query!
Condition category
Condition code
Neurological
331532
331532
0
0
Query!
Other neurological disorders
Query!
Cardiovascular
331592
331592
0
0
Query!
Other cardiovascular diseases
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Once daily, nurse-led administration of dapagliflozin 10mg tablet nasograstrically/orally within 3 hours following comatose cardiac arrest, for 30 days.
Query!
Intervention code [1]
329412
0
Treatment: Drugs
Query!
Comparator / control treatment
Once daily, nurse-led administration of placebo microcrystalline cellulose tablet nasogastrically/orally within 3 hours following comatose cardiac arrest, for 30 days.
Query!
Control group
Placebo
Query!
Outcomes
Primary outcome [1]
339277
0
Composite of adverse events, including mortality, ketoacidosis, renal failure requiring renal replacement therapy, genitourinary infection and hypoglycaemia.
Query!
Assessment method [1]
339277
0
Peripheral blood and urine samples.
Query!
Timepoint [1]
339277
0
Assessed daily for 30 days following comatose cardiac arrest.
Query!
Secondary outcome [1]
439344
0
Biomarkers of hypoxic brain injury (neurofilament light chain)
Query!
Assessment method [1]
439344
0
Peripheral blood samples
Query!
Timepoint [1]
439344
0
Baseline and 72 hours following cardiac arrest
Query!
Secondary outcome [2]
439534
0
Biomarkers of ischaemia-reperfusion injury (C reactive protein)
Query!
Assessment method [2]
439534
0
Peripheral blood samples
Query!
Timepoint [2]
439534
0
At baseline and at 72 hours following cardiac arrest
Query!
Secondary outcome [3]
439537
0
Extent of hypoxic brain injury
Query!
Assessment method [3]
439537
0
Computer tomography
Query!
Timepoint [3]
439537
0
Within 30 days following comatose cardiac arrest
Query!
Secondary outcome [4]
439538
0
Cognitive function
Query!
Assessment method [4]
439538
0
Cerebral performance category score
Query!
Timepoint [4]
439538
0
On discharge from hospital
Query!
Secondary outcome [5]
439947
0
30-day mortality
Query!
Assessment method [5]
439947
0
As documented on hospital records
Query!
Timepoint [5]
439947
0
30 days following cardiac arrest
Query!
Secondary outcome [6]
440156
0
Biomarkers of ischaemia-reperfusion injury (interleukin 6)
Query!
Assessment method [6]
440156
0
Peripheral blood samples
Query!
Timepoint [6]
440156
0
Baseline and at 72 hours post cardiac arrest
Query!
Secondary outcome [7]
440157
0
Biomarkers of ischaemia-reperfusion injury (hypoxic inducible factor 1 alpha)
Query!
Assessment method [7]
440157
0
Peripheral blood samples
Query!
Timepoint [7]
440157
0
At baseline and at 72 hours post cardiac arrest
Query!
Secondary outcome [8]
440158
0
Biomarkers of ischaemia-reperfusion injury (nuclear factor-KB)
Query!
Assessment method [8]
440158
0
Peripheral blood samples
Query!
Timepoint [8]
440158
0
At baseline and at 72 hours post cardiac arrest
Query!
Secondary outcome [9]
440159
0
Biomarkers of ischaemia-reperfusion injury (transforming growth factor beta)
Query!
Assessment method [9]
440159
0
Peripheral blood samples
Query!
Timepoint [9]
440159
0
At baseline and at 72 hours post cardiac arrest
Query!
Secondary outcome [10]
440160
0
Biomarkers of ischaemia-reperfusion injury (tumour necrosis factor alpha)
Query!
Assessment method [10]
440160
0
Peripheral blood samples
Query!
Timepoint [10]
440160
0
At baseline and at 72 hours post cardiac arrest
Query!
Secondary outcome [11]
440161
0
Biomarkers of ischaemia-reperfusion injury (vascular endothelial growth factor)
Query!
Assessment method [11]
440161
0
Peripheral blood samples
Query!
Timepoint [11]
440161
0
At baseline and at 72 hours post cardiac arrest
Query!
Secondary outcome [12]
440162
0
Biomarkers of ischaemia-reperfusion injury (caspase 3)
Query!
Assessment method [12]
440162
0
Peripheral blood samples
Query!
Timepoint [12]
440162
0
At baseline and at 72 hours post cardiac arrest
Query!
Eligibility
Key inclusion criteria
• Consecutive adults aged 18 years or older presenting with comatose out-of-hospital cardiac arrest suspected to be caused by acute coronary syndrome (ACS) as defined as either ST-elevation myocardial infarction (STEMI) or non-ST-elevation myocardial infarction (NSTEMI).
• Total downtime prior to return of spontaneous circulation of less than 30 minutes.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
• Patients with a history of type 1 diabetes
• Patients already treated with an SGLT2 inhibitor
• Patients with an eGFR <25 ml/min/1.73m2 or receiving dialysis
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Sealed opaque envelopes
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using a randomisation table created by computer software
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
Query!
Query!
Query!
Query!
Intervention assignment
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
3/02/2025
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
31/01/2027
Query!
Actual
Query!
Date of last data collection
Anticipated
2/03/2027
Query!
Actual
Query!
Sample size
Target
120
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Funding & Sponsors
Funding source category [1]
317315
0
Self funded/Unfunded
Query!
Name [1]
317315
0
Query!
Address [1]
317315
0
Query!
Country [1]
317315
0
Query!
Primary sponsor type
Hospital
Query!
Name
Alfred Health
Query!
Address
Query!
Country
Australia
Query!
Secondary sponsor category [1]
319597
0
None
Query!
Name [1]
319597
0
Query!
Address [1]
319597
0
Query!
Country [1]
319597
0
Query!
Ethics approval
Ethics application status
Not yet submitted
Query!
Ethics committee name [1]
316047
0
Alfred Hospital Ethics Committee
Query!
Ethics committee address [1]
316047
0
https://www.alfredhealth.org.au/research/ethics-research-governance
Query!
Ethics committee country [1]
316047
0
Australia
Query!
Date submitted for ethics approval [1]
316047
0
24/10/2024
Query!
Approval date [1]
316047
0
Query!
Ethics approval number [1]
316047
0
Query!
Summary
Brief summary
A multi-center, double blind, placebo controlled, randomized pilot study is proposed to evaluate the effects of daily dapagliflozin given within 3 hours of arrest in comatose out-of-hospital cardiac arrest survivors for 30-days post cardiac arrest. The primary end point selected is the safety of dapagliflozin, measured as the total number of in-hospital adverse events. Adverse outcomes will be a composite of in-hospital mortality, ketoacidosis, need for renal replacement therapy, hypoglycaemia, and genitourinary infection. Secondary end points include post-arrest changes in biomarkers (neurofilament light chain, caspase 3, HIF-1a, VEGF, TNF-a, CRP) at 72 hours from baseline, CT-brain defined HIE changes and infarct size, 30-day mortality, and CPC (cerebral performance score) at time of discharge among survivors. This pilot study will aim to include 120 patients, half (n=60) assigned to the dapagliflozin group and half to the placebo. We expect this study will demonstrate the use of dapagliflozin in this population to be safe and effective at reducing biomarkers associated with hypoxic brain injury, allowing for further larger scale trials to explore the potential clinical benefit in reducing hypoxic brain injury in cardiac arrest.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
136606
0
Prof William Chan
Query!
Address
136606
0
The Alfred Hospital, 55 Commercial Road, Melbourne, Victoria, 3004
Query!
Country
136606
0
Australia
Query!
Phone
136606
0
+61 435612868
Query!
Fax
136606
0
Query!
Email
136606
0
[email protected]
Query!
Contact person for public queries
Name
136607
0
Brendan Backhouse
Query!
Address
136607
0
The Alfred Hospital, 55 Commercial Road, Melbourne, Victoria, 3004
Query!
Country
136607
0
Australia
Query!
Phone
136607
0
+61 421189381
Query!
Fax
136607
0
Query!
Email
136607
0
[email protected]
Query!
Contact person for scientific queries
Name
136608
0
Brendan Backhouse
Query!
Address
136608
0
The Alfred Hospital, 55 Commercial Road, Melbourne, Victoria, 3004
Query!
Country
136608
0
Australia
Query!
Phone
136608
0
+61 421189381
Query!
Fax
136608
0
Query!
Email
136608
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF